Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137303 · ClinicalTrials.gov registry record · Phase 3
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT03137303: Completed Phase 3 study, sponsored by University of Illinois at Chicago.
NCT03137303 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 402 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03137303, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
Primary Outcome
Determine differences in healthcare visits which include all-cause and respiratory related, acute care outpatient visits, emergency department visits, and hospitalizations between groups
Interventions
- DRUG Albuterol
- DEVICE Spirometry at initial visit
- DEVICE Spirometry at 12-month follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 3 |
What the finished NCT03137303 record still lists
NCT03137303 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 3 interventions - of which Albuterol is the first listed.
NCT03137303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03137303 about?
NCT03137303 is a clinical study titled "Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)". The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
What is the current status of trial NCT03137303?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2017-07-01. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03137303?
The interventions under investigation include: Albuterol (DRUG), Spirometry at initial visit (DEVICE), Spirometry at 12-month follow-up (DEVICE).
Who is sponsoring clinical trial NCT03137303?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03137303's enrollment target sits among peer trials
402 919th of 2000 higher than 1,080 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI